Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CHIP/CCUS Natural History Protocol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04102423
Recruitment Status : Recruiting
First Posted : September 25, 2019
Last Update Posted : December 16, 2021
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) )

Brief Summary:

Background:

Clonal Hematopoiesis of Indeterminate Potential (CHIP) is a change in a person s DNA that can increase a person s risk of developing blood cancers or cardiovascular disease. CHIP occurs mostly occurs in older people. Clonal cytopenia of undetermined significance (CCUS) occurs when one or more blood cell types is lower than it should be and is associated with a change in their DNA. Researchers want to learn more about how CHIP and CCUS progress.

Objective:

To examine the natural history of people in a study of CHIP and CCUS to (1) verify the association of myeloid somatic mutations with atherosclerosis and blood cancers, and (2) find new potential clinical associations.

Eligibility:

Adults 18 and older with CHIP with a somatic pathogenic variant associated with blood cancers. Adults with CCUS are also needed.

Design:

Potential participants will be screened with gene testing. For this, they will give a blood sample. They will also be enrolled in NHLBI screening protocol #97-H-0041. Those who pass this screening will visit the NIH Clinical Center for more screening tests. For this, they will give a blood sample. They will have a physical exam. They will give their medical history. They may give a urine sample. Those with CCUS will have bone marrow taken.

Eligible participants will give blood and urine samples. Their heart activity will be monitored and tested. The arteries in their neck will be assessed using ultrasound. They will have liver and heart scans. They will have a bone mineral density scan. They will have lung function tests. They will have the inside of their cheek swabbed or have a skin punch biopsy. They will have the option to have advanced scans done of their heart and full body but this is not required.

Participants will have yearly follow-up visits for 10 years. They will repeat the above procedures every 1-3 years depending on the procedure.


Condition or disease
Clonal Hematopoiesis of Indeterminate Potential Clonal Cytopenia of Undetermined Significance

Detailed Description:

Clonal Hematopoiesis of Indeterminate Potential (CHIP) has been defined as the presence of a somatic pathogenic variant associated with hematological malignancy, with an allele fraction of at least 2%, without morphological evidence of bone marrow dysplasia or neoplasia. Such variants are small, occur in leukocytes and are found in a substantial proportion of the healthy aging population using next generation sequencing (NGS). They are thought to represent a pre-neoplastic phase of hematological malignancy, particularly myeloid disorders such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). They are considered by some to be analogous to monoclonal B cell lymphocytosis (MBL), or monoclonal gammopathy of uncertain significance (MGUS) as precursors for chronic lymphocytic leukemia (CLL) and myeloma respectively, and, with a similar rate of progression of 0.5%-1% per year.

CHIP is strongly associated with advancing age with a prevalence of up to 10% in those >65 years of age compared to 1% in those <50 years of age, and has also been associated with an increased atherosclerotic risk], and an increase in overall mortality. Despite this association most people with CHIP are denoted healthy and do not progress to hematological malignancy. Those with low blood counts in association with a - termed clonal cytopenias of undetermined significance (CCUS) - do show a significantly higher rate of progression to myeloid malignancy, more analogous to patients with low risk MDS, though they are currently not classified as such as they lack the morphological dysplasia or defining chromosomal abnormalities.

The optimal follow-up and management of CHIP and CCUS is not yet established - evidence has suggested that factors such as which specific variant, how many variants are present, and the frequency at which these variants increase can help us to delineate high and low risk status. Some recent data has shown that the presence of CHIP is associated with increased levels of inflammation. In depth investigation should provide further insight into the pathogenesis and progression of this process. The establishment of a natural history protocol will allow patients with CHIP and CCUS to be followed prospectively in a clinical setting. This protocol will have many collaborators from different institutes providing expertise including National Human Genome Research Institute (NHGRI), National Heart, Lung and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the Department of Laboratory Medicine (DLM).

Layout table for study information
Study Type : Observational
Estimated Enrollment : 306 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Investigation of the Natural Progression of Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance.
Actual Study Start Date : March 3, 2020
Estimated Primary Completion Date : September 15, 2033
Estimated Study Completion Date : September 15, 2033

Resource links provided by the National Library of Medicine


Group/Cohort
CCUS
All participants meeting the criteria for CCUS
CHIP
Subjects will be split into five cohorts depending on specific mutations



Primary Outcome Measures :
  1. Verify the previously studied association of myeloid somatic mutations with hematological malignancy [ Time Frame: 10 years ]
    Association of myeloid somatic mutations with hematological malignancy

  2. Verify the previously studied association of myeloid somatic mutations with atherosclerosis [ Time Frame: 10 years ]
    Association of myeloid somatic mutations with atherosclerosis

  3. Immune response [ Time Frame: 10 years ]
    Assessing immune response by measuring markers of inflammation

  4. Examine potential new clinical associations [ Time Frame: 10 years ]
    New clinical associations

  5. Development of cytopenia, hematological malignancy, and the size and stability of leucocyte somatic mutations [ Time Frame: 10 years ]
    Cytopenia, hematological malignancy, and the size and stability of leucocyte somatic mutations


Secondary Outcome Measures :
  1. Relationship between CHIP/CCUS and chronic viral infections such as CMV, EBV, HSV, HIV, Hepatitis B and Hepatitis C [ Time Frame: 10 years ]
    To establish whether there is a relationship between CHIP/CCUS and chronic viral infections such as CMV, EBV, HSV, HIV, Hepatitis B and Hepatitis C

  2. Relationship between CHIP/CCUS and atherosclerosis, diabetes, and metabolic syndrome [ Time Frame: 10 years ]
    To establish whether there is a relationship between CHIP/CCUS and atherosclerosis, diabetes, and metabolic syndrome

  3. Correlation between CHIP/CCUS and vitamin levels [ Time Frame: 10 years ]
    To establish whether there is a correlation between CHIP/CCUS and vitamin levels

  4. Correlation between CHIP/CCUS and chronic renal impairment [ Time Frame: 10 years ]
    To establish whether there is a correlation between CHIP/CCUS and chronic renal impairment

  5. Correlation between CHIP/CCUS and chronic lung disease [ Time Frame: 10 years ]
    To establish whether there is a correlation between CHIP/CCUS and chronic lung disease

  6. Correlation between CHIP/CCUS and chronic liver disease [ Time Frame: 10 years ]
    To establish whether there is a correlation between CHIP/CCUS and chronic liver disease



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary Clinical
Criteria
  • Participants with Clonal Hematopoiesis of Indeterminate Significance (CHIP):

INCLUSION CRITERIA:

  • Greater than or equal to 18 years of age
  • Willingness and capacity to provide written informed consent
  • Presence of a somatic pathogenic variant associated with hematological malignancy
  • Variant allele fraction of greater than or equal to 2% in at least one identified somatic pathogenic variant

EXCLUSION CRITERIA:

  • Known diagnosis of a hematological malignancy or bone marrow failure syndrome (excluding MGUS or MBL)
  • Presence of a cytopenia:

    --Hemoglobin, <10 g/dL; platelet count, <100x10(9) /L; or absolute neutrophil count, <1.5x10(9) /L

  • Pregnant at the time of recruitment
  • Treatment with previous chemotherapy or radiotherapy

Participants with Clonal Cytopenia of Uncertain Significance (CCUS):

INCLUSION CRITERIA:

  • Greater than 18 years of age
  • Willingness and capacity to provide written informed consent
  • Presence of a somatic pathogenic variant associated with hematological malignancy without morphological evidence of

myelodysplasia and without a MDS defining cytogenetic abnormality

  • Variant allele fraction of greater than or equal to 2% in at least one identified somatic pathogenic variant
  • Bone marrow aspirate and biopsy excluding hematological malignancy and MDS
  • Presence of a cytopenia for >30 days

    • Hemoglobin, <10 g/dL; platelet count, <100x10(9) /L; or absolute neutrophil count, <1.5x10(9) /L
    • At least 2 CBCs documented in a non-hospitalized patient at least 3 days apart

EXCLUSION CRITERIA:

  • Known diagnosis of a hematological malignancy or bone marrow failure syndrome (excluding MGUS or MBL)
  • Morphological evidence of dysplasia on bone marrow aspirate / biopsy 10% dysplastic cells in any hematopoietic lineage
  • Ringed sideroblasts >15%
  • Presence of MDS defining cytogenetic abnormality

    • del(7q)
    • del(5q)
    • 17q or t(17p)
    • del(13q)
    • del(11q)
    • del(12p) or t(12p)
    • del(9q)
    • idic(X)(q13)
    • t(11;16)
    • t(3;21)
    • t(1;3)
    • t(2;11)
    • inv(3)/t(3;3)
  • t(6;9)

    --Note: As a sole cytogenetic abnormality in the absence of morphological criteria, gain of chromosome 8, del(20q) and loss of chromosome Y are not considered definitive evidence of MDS.

  • Alternate hematological diagnosis causing cytopenia
  • Pregnant at time of recruitment
  • Previous chemotherapy or radiotherapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04102423


Contacts
Layout table for location contacts
Contact: Ivana Darden, R.N. (301) 827-2988 ivana.darden@nih.gov

Locations
Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: Neal Young, M.D.    301-496-5093    youngns@mail.nih.gov   
Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Layout table for investigator information
Principal Investigator: Emma M Groarke, M.D. National Heart, Lung, and Blood Institute (NHLBI)
Additional Information:
Layout table for additonal information
Responsible Party: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier: NCT04102423    
Other Study ID Numbers: 190139
19-H-0139
First Posted: September 25, 2019    Key Record Dates
Last Update Posted: December 16, 2021
Last Verified: November 30, 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) ):
Cytopenia
Myelodysplastic Syndrome
Somatic Mutations
Natural History
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia
Leukopenia
Thrombocytopenia
Hematologic Diseases
Leukocyte Disorders
Blood Platelet Disorders